Conditions: Non-small Cell Lung Cancer
Keywords: BRIDGE NSCLC Lung Cancer Avastin
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 47
Healthy volunteers: no

Brief summary:
This is an open-label, single-arm, multicenter pilot study to evaluate the safety and efficacy of carboplatin/paclitaxel+bevacizumab in subjects with locally advanced (Stage IIIb with pleural effusion/pericardial effusion), Stage IV, or recurrent squamous Non-Small Cell Lung Cancer (NSCLC) who have not received prior systemic therapy for metastatic disease.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Bevacizumab intervention 2: Carboplatin intervention 3: Paclitaxel
Intervention descriptions: intervention 1: 15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3 intervention 2: Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles intervention 3: Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles

Protocol document: